Sociedad Americana de Hirudoterapia

Rickettsia japonica infection after land leech bite, Japan

Case report published in Emerg Infect Dis (2019)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportSeguridad y control de infeccionesSando E et al. · Emerging infectious diseases, 2019

Abstract

We report a case of Rickettsia japonica infection in an 81-year-old man in central Japan. The patient had fever, rash, and an eschar but no evidence of a tick bite. His symptoms began 8 days after a land leech bite. The land leech is a potential vector of R. japonica.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsLetterResearch Support, Non-U.S. Gov't
Indexed MeSH termsAged, 80 and overAnimalsBiomarkersBites and StingsExanthemaFluorescent Antibody TechniqueHumansJapanLeechesMalePolymerase Chain ReactionRickettsia

Resumen

81-year-old man in central Japan with fever, rash, and eschar 8 days after land-leech bite, confirmed Rickettsia japonica infection. Land leech identified as potential vector.

Por qué esto importa para la hirudoterapia

This case report describes an 81-year-old man in central Japan who developed Rickettsia japonica infection (fever, rash, eschar) with symptom onset eight days after a land leech bite and no evidence of a tick bite. The authors propose the land leech as a potential vector of R. japonica. This relates to ASH's domain only as documentation of an infectious complication following leech exposure, contributing to awareness of risks associated with leech bites. The case involves a wild land leech bite, not therapeutic hirudotherapy, and does not address the medicinal leech secretome, anticoagulant activity, or controlled leech application. It is a single case report establishing only a possible vector relationship.

Citación

Rickettsia japonica infection after land leech bite, Japan.

Sando E et al. · Emerging infectious diseases, 2019

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.